You are here: Industry Insights > MSK

News List

Sanofi to license multiple myeloma target domain from Eureka and MSK pharmaceutical-technology
July 08, 2021
Sanofi has signed a licence agreement with Eureka Therapeutics and Memorial Sloan Kettering Cancer Center (MSK) for non-CAR use of a new human binding domain for the potential treatment of multiple myeloma.
Actinium Initiates Patient Enrollment in Iomab-ACT Trial americanpharmaceuticalreview
April 01, 2021
Actinium Pharmaceuticals announced its collaborator, Memorial Sloan Kettering Cancer Center (MSK), has commenced patient enrollment in the Phase 1 study evaluating Iomab-ACT for targeted conditioning prior to treatment with MSK's CD19 targeted ...
Common cancer treatments do not worsen COVID-19 infection, study finds europeanpharmaceuticalreview
June 30, 2020
A study has found that chemotherapy and surgery do not correlate with worse COVID-19 outcomes for cancer patients, whereas taking immune checkpoint inhibitors does.
Takeda strikes three new immuno-oncology deals pharmaphorum
January 07, 2019
Takeda is upping its commitment to cancer after its Shire takeover with the announcement of three new research collaborations in immuno-oncology.....
Takeda announces multiple cell therapy collaborations biospectrumasia
January 04, 2019
New collaborations expand Takeda’s commitment to pursue the discovery of novel cell therapy approaches to treat blood cancers and solid tumors.